SGLT2 inhibitors have proven cardiovascular and kidney benefits in patients with type 2 diabetes (T2D) (Heerspink et al., 2016, 2018; Zinman et al., 2015). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.